Recon: Lawmakers want opioid settlement tax breaks examined; Pfizer stops clinical trials in Russia but will continue to send drugs

• US should review drugmakers' opioid settlement tax breaks -House panel (Reuters) (Bloomberg)
• Astra, Merck’s Lynparza Approved in US as Adjuvant Treatment (Bloomberg)
• FDA declines to approve AstraZeneca treatment for chronic nasal condition (Reuters) (Endpoints)
• FDA orders Incyte to hold up yet again in the hunt for blockbuster franchise (Endpoints)
• Appeals court sides with Bristol Myers Squibb in years-long battle with investors over Opdivo fail (Endpoints)
• What to know about Amylyx’s ALS drug and a highly anticipated advisory panel meeting (STAT)
• Rhode Island takes Teva to trial in multibillion-dollar opioid case (Reuters)
• In New York appearance, CMS administrator pushes for Congress to act on drug prices (STAT)

• Pfizer Pauses Trials in Russia, Will Continue to Send Drugs (Bloomberg) (Endpoints)
• WHO says it advised Ukraine to destroy pathogens in health labs to prevent disease spread (Reuters)
• Pfizer’s Covid Pill Unlikely to Reach Much of World for a Year (Bloomberg)
• Novel Malaria Treatment for Children Receives First Approval (NYT)
• India CEOs On Automated Plants, New Modalities, Tackling 'The Great Talent Reshuffle' (Scrip)

• COVAX & Team Europe ‘Not Structural Solutions’ To COVID-19 Vaccine Inequity (The Pink Sheet)
• Pfizer Signs Paxlovid Agreement As China Cases Soar (Scrip)
• Which Coronavirus Vaccine Will Work in the Youngest Children? (NYT)
• Mexico to uphold existing agreements for Russian COVID vaccine (Reuters)

• Sanofi Cancer Drug Setback Hobbles Potential Blockbuster (Bloomberg) (Fierce)
• Top 10 pharma R&D budgets in 2021 (Fierce)
• BMS-Nektar’s Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech history (Fierce) (STAT)
• BridgeBio plots path to market for muscular dystrophy drug after posting phase 2 data (Fierce)
• After first FDA win last year, Ascendis touts a new PhIII success in hypoparathyroidism (Endpoints)
• GMP-in-a-box company with Bob Nelsen backing lands $167M to develop its own cancer drugs (Endpoints)
• With a make-or-break PhIII readout looming, a struggling Concert offloads a 'portfolio' of drugs (Endpoints)

• MDCG Meeting Updates Expected To Break Implementation Silence On EU IVDR (MedTech Insight)
• Minute Insight: Philips’ Collaboration Live Ultrasound Platform Gets 510(k) For Mobile Devices (MedTech Insight)
• Dexcom’s next-gen G7 diabetes sensor scores European approval (Fierce)
• FDA upgrades Baxter infusion pump safety issues to Class I recall (Fierce)
• ZimVie CEO talks company spinoff, new technologies (MedTech Dive)

• Key Opioid Cases To Watch As Massive Wave Of Trials Looms (Law360)
• Balwani Wants Altered Theranos Pharma Reports Out Of Trial (Law360)
• Cigna Gets $6 Million Covid Testing Reimbursement Suit Trimmed (Bloomberg)
• SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law (The Pink Sheet)